Sarepta Therapeutics, Inc.
SRPT Healthcare Biotechnology
Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue fell 34.3%, EPS fell 102.5%, free cash flow fell 14.5% and total debt fell 25.6%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
Follow SRPT
Sarepta Therapeutics, Inc. (SRPT) P/E ratio
Sarepta Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 1,170× (June 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 49.6× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 35.3× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 34 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MRVI Maravai LifeSciences Holdings, Inc. compare | n/m |
| PVLA Palvella Therapeutics, Inc. compare | n/m |
| MESO Mesoblast Limited compare | n/m |
| MLYS Mineralys Therapeutics, Inc. compare | n/m |
| URGN Urogen Pharma compare | n/m |
| ZYME Zymeworks Inc. compare | n/m |
| AGIO Agios Pharmaceuticals, Inc. compare | n/m |
| SRPT Sarepta Therapeutics, Inc. | n/m |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)